Syndax shares slide despite pivotal trial success

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint.

The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small molecule menin inhibitor has shown potential in targeting specific genetic mutations associated with AML.

People treated with revumenib scored an average 23% complete remission rate, with a median duration of 4.7 months, and some still sustaining their response at the time of data analysis. The overall response rate reached 47%, with nearly one in five patients able to proceed to hematopoietic stem cell transplantation after treatment.